Synamics Therapeutics, AI-Driven Drug Discovery Startup, Attracts Former Novozymes Executives as Lead Investors

Copenhagen, Denmark – July 16, 2024 – Synamics Therapeutics, a groundbreaking AI-driven drug discovery startup dedicated to combating drug resistance in cancer, proudly announces a lead investment in its pre-seed round, from two prominent figures in the biotechnology industry. Steen Riisgaard and Per Falholt have backed Synamics Therapeutics as lead investors. Riisgaard, former CEO of Novozymes, member of the Novo Nordisk Foundation’s board, and esteemed biotech investor and Falholt, former Chief Scientific Officer of Novozymes and current Chief Scientific Officer at 21st.BIO, bring their